StockData

Smith & Nephew vs Zimmer Biomet

SNN and ZBH side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SNN and ZBH compare

Zimmer Biomet grew revenue faster over the last twelve months (8.6% versus 6.1% for Smith & Nephew).

Zimmer Biomet pays a dividend yielding 1.0%; Smith & Nephew does not pay one.

Zimmer Biomet scores higher on the StockData Score (17 against 6 for Smith & Nephew), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSNNZBH
Size and price
Market cap–$18.0B
Share price$29.70$94.52
Change, 1 year−17.0%−5.2%
Change, 5 years−20.1%−33.3%
Beta (5Y)0.630.69
Employees18K17K
StockData Score
Total score617 (better)
Valuation score06 (better)
Growth score11
Performance score13 (better)
Health score4 (better)3
Dividend score04 (better)
Valuation
P/E–23.0×
P/S–2.1×
P/B–1.4×
EV/EBITDA–10.9×
P/FCF–11.8×
PEG–0.48
FCF yield–8.4%
Fair value–$124.06
Margin of safety–23.8%
Growth
Revenue growth (TTM)6.1%8.6% (better)
Revenue growth, 5Y average6.2% (better)6.1%
Net income growth (TTM)–−2.0%
EPS growth (TTM)52.3% (better)0.00%
EPS growth, 5Y average6.9%–
Profitability
Gross margin68.0%69.9% (better)
Operating margin12.9%14.2% (better)
Net margin–9.5%
FCF margin–17.9%
Return on equity–6.4%
Return on invested capital13.0% (better)5.3%
Financial health
Debt / equity0.10 (better)0.59
Net debt / EBITDA−0.313.06 (better)
Interest coverage5.7×–
Current ratio2.14 (better)1.69
Altman Z-score–2.46
Piotroski F-score–6
Dividends and buybacks
Dividend yield–1.0%
Payout ratio–23.4%
Years of dividend growth–0
Dividend growth, 5Y average–0.00%
Buyback yield–4.2%
Shareholder yield–5.2%
Ownership
Held by institutions4.2%104%
Held by insiders25.1%0.18%
Insider net buying, 12 months–−$1.6M
Superinvestors holding–1
Short interest, % of float–5.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.